Ardelyx Posts Strong 2025 Results, Projects 2026 Growth
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ardelyx ( (ARDX) ) just unveiled an announcement.
On February 19, 2026, Ardelyx reported its fourth-quarter and full-year 2025 results, highlighting a 73% surge in IBSRELA revenue to $274.2 million and total revenue of $407.3 million, alongside $103.6 million from XPHOZAH. Despite higher R&D and SG&A expenses tied to commercialization and pipeline investments, the company ended 2025 with $264.7 million in cash and a net loss of $61.6 million, while projecting strong 2026 revenue growth for both products and outlining plans to expand IBSRELA’s indications and advance a next-generation NHE3 inhibitor, underpinned by new patent protection extending to 2042.
Ardelyx also detailed strategic progress including a Phase 3 ACCEL trial of tenapanor in chronic idiopathic constipation initiated in early 2026, a development program for new NHE3 inhibitor RDX10531, and increased scientific visibility through multiple poster presentations at major nephrology and gastroenterology meetings. The issuance of a new U.S. patent covering the commercial formulations of IBSRELA and XPHOZAH, along with a patient-first strategy that has supported XPHOZAH uptake, strengthens Ardelyx’s competitive position and supports its ambition to grow IBSRELA into a billion-dollar franchise by 2029.
The most recent analyst rating on (ARDX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.
Spark’s Take on ARDX Stock
According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.
The score is led by strong technical momentum and a constructive earnings call with raised IBSRELA guidance and solid product revenue growth. Offsetting these positives are weak core financial profitability, higher balance-sheet leverage, and a negative P/E due to continuing losses.
To see Spark’s full report on ARDX stock, click here.
More about Ardelyx
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for patients with significant unmet medical needs. Its key products include IBSRELA, approved for irritable bowel syndrome with constipation in adults, and XPHOZAH, both based on tenapanor and targeting gastrointestinal and kidney-related disorders in the U.S. market.
Average Trading Volume: 4,121,340
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.64B
For an in-depth examination of ARDX stock, go to TipRanks’ Overview page.
